Argitalpenak (28) ÁLVARO PRADA IÑURRATEGUI argitalpenak

2024

  1. Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))

    Autoimmunity Reviews

2023

  1. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome

    Journal of Translational Medicine, Vol. 21, Núm. 1

  2. Early biochemical analysis of COVID-19 patients helps severity prediction

    PLoS ONE, Vol. 18, Núm. 5 May

  3. Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection

    Frontiers in Aging, Vol. 4

  4. In-depth blood immune profiling of Good syndrome patients

    Frontiers in Immunology, Vol. 14

  5. Laboratory and clinical practices in antinuclear antibody detection and related antigens: recommendations from a Spanish multicentre survey

    Immunologic Research, Vol. 71, Núm. 5, pp. 749-759

  6. Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel

    Autoimmunity Reviews, Vol. 22, Núm. 12

2022

  1. Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder?

    Journal of Translational Medicine, Vol. 20, Núm. 1

2021

  1. Autoimmune GFAP astrocytopathy presenting with remarkable CNS hyperexcitability and oculogyric crises

    Journal of Neuroimmunology, Vol. 359

  2. O group is a protective factor for COVID19 in Basque population

    PLoS ONE, Vol. 16, Núm. 4 April

  3. The age again in the eye of the COVID-19 storm: evidence-based decision making

    Immunity and Ageing, Vol. 18, Núm. 1

2020

  1. COVID-19: Age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study

    Immunity and Ageing, Vol. 17, Núm. 1

  2. Whole-transcriptome analysis in peripheral blood mononuclear cells from patients with lipid-specific oligoclonal igm band characterization reveals two circular RNAs and two linear rnas as biomarkers of highly active disease

    Biomedicines, Vol. 8, Núm. 12, pp. 1-16

2019

  1. ABO blood group distributions in multiple sclerosis patients from Basque Country; O- as a protective factor

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 5, Núm. 4

  2. Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis

    Clinica Chimica Acta, Vol. 488, pp. 135-142

2018

  1. The first dose of fingolimod affects circulating extracellular vesicles in multiple sclerosis patients

    International Journal of Molecular Sciences, Vol. 19, Núm. 8

2015

  1. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

    Clinica Chimica Acta, Vol. 438, pp. 67-69

  2. Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis

    BMC Genomics, Vol. 16, Núm. 1

  3. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

    Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457

2014

  1. Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis

    Biomarkers in Medicine, Vol. 8, Núm. 5, pp. 653-661